The United Laboratories International (03933.HK): UBT48128 Tablets Obtain US FDA Clinical Trial Approval
NewTimeSpace News: On 11 August 2026, The United Laboratories International (03933.HK) announced that UBT48128 Tablets, a Class 1 innovative drug self-developed by its wholly-owned subsidiary United Biotech, has received Investigational New Drug (IND) approval from the US FDA.
According to the announcement, UBT48128 is a small-molecule GLP‑1 receptor agonist. It works by stimulating insulin secretion, suppressing appetite and regulating energy metabolism to lower blood glucose and induce weight loss.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- United Lab(3933.HK) gets US$9M second milestone from Novo for UBT251
- UNITED LAB (03933.HK): NMPA Accepts Filing for IDegLira; First Chinese Biosimilar Applicant
- UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China
- UNITED LAB (03933.HK): Receives US$13.5 Million Milestone Payment from Novo Nordisk for UBT251
